Overall survival and event-free survival from randomization. (A) Overall survival (OS) from randomization. With a median follow-up of 53 months, the 4-year OS was 48% for the TRIL cohort (blue line) and 51% for the DLBCL cohort (red line) (P = .61). (B) Event-free survival (EFS) from randomization. With a median follow-up of 53 months, the 4-year EFS was 26% for the TRIL cohort (blue line) and 27% for the DLBCL cohort (red line) (P = .61).